May Measurement Month 2022: an analysis of blood pressure screening results from Albania

Gentiana Qirjako, Genc Burazeri(University of Medicine Tirana), Thomas Beaney(Imperial College London), Sonila Bele(University of Medicine Tirana), Rudina Çumashi(University of Medicine Tirana), Xheladin Draçini(University of Medicine Tirana), Gabriele Kerr(Imperial College London), Neil R Poulter(Imperial College London), Eugena Tomini(University of Medicine Tirana), Romina Hala(University of Medicine Tirana), Alban Ylli(University of Medicine Tirana)
European Heart Journal Supplements
February 10, 2025
10.1093/eurheartjsupp/suaf055
Cited by 1

Related Papers

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
|The Lancet|2003|3.8k
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
|The Lancet|2005|2.9k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k